Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:codeine
chlorpheniramine |
| gptkbp:approvalYear |
2015
|
| gptkbp:ATCCode |
R05DA04
|
| gptkbp:broadcastOn |
gptkb:Schedule_III_controlled_substance_(US)
|
| gptkbp:contraindication |
patients with respiratory depression
children under 18 years patients with hypersensitivity to codeine or chlorpheniramine |
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:form |
gptkb:sugar
extended-release oral suspension |
| https://www.w3.org/2000/01/rdf-schema#label |
Tuzistra XR
|
| gptkbp:indication |
cough
upper respiratory symptoms |
| gptkbp:manufacturer |
gptkb:Tris_Pharma
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:riskFactor |
respiratory depression
sedation abuse potential |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
constipation dizziness drowsiness |
| gptkbp:bfsParent |
gptkb:Azurity_Pharmaceuticals
gptkb:Arbor_Pharmaceuticals |
| gptkbp:bfsLayer |
8
|